Pharma Focus Asia

CTP-543 Novel Therapy Introduced for the Treatment of Alopecia Areata

Concert Pharmaceuticals, Inc introduces CTP-543, Oral Janus kinase inhibitor for the treatment of moderate-to-severe alopecia areata in adult patients.

Alopecia areata, is an autoimmune disorder in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body.It affects approximately 700,000 Americans. In this particular disease scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp appearing throughout life infecting both men and women. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression.

CTP-543therapy is applicable for the treatment of alopecia areata. Treatment with CTP-543 was well tolerated by patients.

FDA Breakthrough Therapy Designation for CTP-543was done based on the positive results from Phase 2 clinical trial in patients with moderate-to-severe alopecia areata.

US Food and Drug Administration (FDA)grants Breakthrough Therapy Designation for CTP-543 for the treatment of alopecia areata.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024